BioCell Innovation’s CRS-Safe CAR-T Process Gets Boost from ScaleReady G-Rex® Grant

BioCell Innovations Pte Ltd, a Singapore-based biotechnology company pioneering next-generation CAR-T therapies, announced today that it has been awarded a G-Rex® Grant (USD$125,000) from ScaleReady to integrate our proprietary CAR manufacturing process with the highly efficient G-Rex platform. BioCell Innovations has introduced a proprietary CAR-T manufacturing process that dramatically reduces cytokine-associated toxicities, particularly cytokine release […]

Read More
Memorandum of Understanding & Collaboration Agreement Signing Ceremony

BioCell Innovations Pte Ltd has recently signed a Memorandum of Understanding with Thermo Fisher Scientific Pte Ltd (a subsidiary of Thermo Fisher Scientific Inc) aiming to optimize a closed process for the clinical manufacturing of lentiviral-based immunotherapies within the Asia-Pacific region. We are excited to collaborate and to support new opportunities by bringing together BioCell […]

Read More
Presentations

Conference (Poster) Presentation Period Title of Presentation 3rd Cell and Gene Therapy R&D Congress Asia Apr 2025 Development of humanized CD19/CD20 bispecific CAR-T cells for enhanced targeting in B-cell malignancies Singapore Cell and Gene Therapy Pan Asia Summit, Singapore Jul 2024 Accelerated CD19 CAR T-cell Manufacturing with Enhanced Vector Transduction and Reduced Risk of CRS […]

Read More